Opsidio Reports 1st Patient Dosing in P-IIa (Opscf-201) Study for the Treatment Of Atopic Dermatitis
Shots:
- The P-IIa (OpSCF-201) study evaluating safety & efficacy of OpSCF vs PBO in treating adults (n=84) with moderate to severe atopic dermatitis (AD)
- The 1EP of the study includes percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while 2EPs include safety and tolerability and improvement in pruritus, body surface area, and quality of life
- In a previous phase 1a/b study involving 115 subjects, OpSCF exhibited safety and favorable tolerance during both single and multiple ascending dose administrations in healthy volunteers. OpSCF, a mAb, specifically targets the SCF248 isoform of stem cell factor, addressing the inflammatory pathway in AD
Ref: PR Newswire | Image: Opsidio
Related News:- EpimAb Biotherapeutics Entered into a License Agreement with Almirall to Develop Bispecific Antibody
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
